GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Book Value per Share

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Book Value per Share : $1.49 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Book Value per Share?

Arrowhead Pharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was $1.49.

During the past 12 months, Arrowhead Pharmaceuticals's average Book Value Per Share Growth Rate was -58.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -17.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 16.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arrowhead Pharmaceuticals was 60.60% per year. The lowest was -62.80% per year. And the median was -5.10% per year.

Arrowhead Pharmaceuticals's current price is $21.87. Its book value per share for the quarter that ended in Dec. 2023 was $1.49. Hence, today's PB Ratio of Arrowhead Pharmaceuticals is 14.66.

During the past 13 years, the highest P/B Ratio of Arrowhead Pharmaceuticals was 28.51. The lowest was 0.91. And the median was 8.03.


Arrowhead Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Book Value per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 4.51 3.92 3.76 2.53

Arrowhead Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.55 4.18 3.41 2.53 1.49

Competitive Comparison of Arrowhead Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's PB Ratio falls into.



Arrowhead Pharmaceuticals Book Value per Share Calculation

Arrowhead Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Sep. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(271.3-0.0)/107.3
=2.53

Arrowhead Pharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(160.4-0.0)/107.5
=1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Arrowhead Pharmaceuticals  (NAS:ARWR) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Arrowhead Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Executives
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105